Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Pharma shares extended gains for the fourth consecutive trading session.
At 11:25 IST, the barometer index, the S&P BSE Sensex jumped 341.41 points or 0.45% to 74,497.54. The Nifty 50 index rose 106.10 points or 0.47% to 23,044.30.
The broader market underperformed the frontline indices. The Nifty MidCap 150 Index rose declined 0.78% and the Nifty SmallCap 250 Index fell 1.44%.
The market breadth was weak. On the BSE, 961 shares rose and 2, 339 shares fell. A total of 99 shares were unchanged.
Initial Public offer (IPO)
M. K. Sons Fine Jewels received bids for 2,32,89,721 shares as against 1,19,00,000 crore shares on offer, according to stock exchange data at 11:25 IST on 29 October 2026. The issue was subscribed 1.96 times.
The issue opened for bidding on 28 October 2026 and will close on 30 October 2026. The price band of the IPO is fixed between Rs 153 and 162 per share. An investor can bid for a minimum of 91 equity shares and multiples thereof.
Bombay Coated & Special Steels received bids for 5,10,60,282 shares as against 1,65,33,012 shares on offer, according to stock exchange data at 11:25 IST on 29 October 2026. The issue was subscribed 3.09 times.
The issue opened for bidding on 29 October 2026 and will close on 2 November 2026. The price band of the IPO is fixed between Rs 78 and 82 per share. An investor can bid for a minimum of 182 equity shares and multiples thereof.
Buzzing Index:
The Nifty Pharma index jumped 1.59% to 27,136.10. The index surged 7.13% in the four consecutive trading sessions.
Laurus Labs (up 4.89%), Zydus Lifesciences (up 4.02%), Piramal Pharma (up 3.44%), Sai Life Sciences (up 2.57%) and Sun Pharmaceutical Industries (up 1.73%), Divis Laboratories (up 1.55%), Torrent Pharmaceuticals (up 1.44%), Mankind Pharma (up 1.41%), Ajanta Pharma (up 0.9%) and Gland Pharma (up 0.76%) surged.
Global Market:
Dow futures fell 107 points, signalling a negative opening for US stocks.
Asian equities came under pressure on Friday as Bank of Japan (BOJ) kept interest unchanged at 1.25%. The BOJ also upgraded its inflation forecast for its fiscal year 2027 to 2.6% from 2.4%, with the so-called “core-core” inflation forecast also raised to 2.7% from 2.6%
US stocks ended lower on Thursday, as disappointing technology earnings and concerns over AI investment returns weighed on investor sentiment. The Dow Jones Industrial Average declined 132.54 points, or 0.25%, to 52,342.56. The S&P 500 fell 23.59 points, or 0.30%, to 7,720.39, while the Nasdaq Composite dropped 365.13 points, or 1.38%, to 26,184.72.
Alphabet shares plunged 12.64% on Thursday, marking their worst daily decline on record, after its third-quarter revenue missed market expectations. Revenue increased 25% year on year to $127.58 billion, against the analyst estimate of $127.97 billion. Earnings per share stood at $2.12, below expectations of approximately $2.94.
Google Cloud revenue surged 103% to $30.7 billion, but concerns over heavy AI-related capital expenditure and the returns from these investments overshadowed the growth.
ServiceNow and Fortinet also faced heavy selling following their financial updates. Both stocks declined more than 20%, adding to pressure on the technology sector.
After the US market close, Intel shares plunged more than 17% in extended trading after the company issued a weaker-than-expected outlook. Intel reported third-quarter revenue of $16.5 billion, up 21% year on year, and non-GAAP earnings per share of $0.52. It forecast fourth-quarter revenue of $15 billion to $16 billion and non-GAAP earnings per share of $0.25.
Amazon shares fell more than 5% in extended trading despite strong cloud growth. Third-quarter net sales increased 12% to $201.94 billion, while AWS revenue rose 39% to $46 billion. Operating income increased to $28.08 billion from $17.42 billion a year earlier.
However, trailing 12-month free cash flow turned negative at $42.36 billion, compared with positive free cash flow of $14.79 billion a year earlier. Amazon maintained its 2026 capital expenditure forecast of approximately $220 billion. Its fourth-quarter revenue guidance of $240 billion to $247 billion also disappointed investors.
The US economy expanded at an annualised rate of 3.4% in the third quarter of 2026, according to the advance estimate released by the Bureau of Economic Analysis on Thursday. This compared with growth of 2.2% in the second quarter and exceeded the approximately 3% market forecast.
Consumer spending rose at a 3.8% annualised rate, while business investment also contributed to growth. Investment in information-processing equipment increased sharply, reflecting continued spending on AI-related infrastructure. The GDP figure is preliminary and subject to revision.
Meanwhile, the Personal Consumption Expenditures (PCE) price index, the Federal Reserve's preferred inflation gauge, increased 0.5% month on month in September, compared with 0.3% in August. Annual inflation accelerated to 3.6% from 3.4%.
Core PCE inflation, excluding food and energy, rose 0.3% month on month and 3.1% year on year, compared with 3.0% in August. The monthly increases were in line with market expectations.
Personal consumption expenditure increased 0.5% in September, while real consumer spending was unchanged. The data indicated that inflationary pressures remained elevated despite resilient economic growth.
Trent Ltd, Zydus Lifesciences Ltd, Shaily Engineering Plastics Ltd and Laurus Labs Ltd are among the other gainers in the BSE's 'A' group today, 30 October 2026.
Greaves Cotton Ltd soared 8.10% to Rs 202.75 at 11:45 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 4.17 lakh shares were traded on the counter so far as against the average daily volumes of 67015 shares in the past one month.
Trent Ltd surged 6.14% to Rs 3041.85. The stock was the second biggest gainer in 'A' group. On the BSE, 2.43 lakh shares were traded on the counter so far as against the average daily volumes of 72203 shares in the past one month.
Zydus Lifesciences Ltd spiked 5.14% to Rs 1247. The stock was the third biggest gainer in 'A' group. On the BSE, 1.55 lakh shares were traded on the counter so far as against the average daily volumes of 61655 shares in the past one month.
Shaily Engineering Plastics Ltd gained 4.92% to Rs 3207.65. The stock was the fourth biggest gainer in 'A' group. On the BSE, 19664 shares were traded on the counter so far as against the average daily volumes of 9118 shares in the past one month.
Laurus Labs Ltd exploded 4.90% to Rs 2354.9. The stock was the fifth biggest gainer in 'A' group. On the BSE, 4.24 lakh shares were traded on the counter so far as against the average daily volumes of 99097 shares in the past one month.
Zydus Lifesciences Ltd rose for a fifth straight session today. The stock is quoting at Rs 1241.5, up 4.82% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.72% on the day, quoting at 23102.8. The Sensex is at 74685.25, up 0.72%. Zydus Lifesciences Ltd has added around 8.36% in last one month.
Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has added around 3.43% in last one month and is currently quoting at 26710.8, up 1.88% on the day. The volume in the stock stood at 21.09 lakh shares today, compared to the daily average of 13.2 lakh shares in last one month.
The benchmark November futures contract for the stock is quoting at Rs 1247.4, up 4.24% on the day. Zydus Lifesciences Ltd is up 27.41% in last one year as compared to a 10.18% fall in NIFTY and a 22.72% fall in the Nifty Pharma index.
The PE of the stock is 32.46 based on TTM earnings ending June 26.
Zydus Lifesciences (Zydus) today announced that the United States Food and Drug Administration (USFDA) has granted final approval for its Abbreviated New Drug Application (ANDA) for Estradiol and Levonorgestrel Transdermal System, 0.045 mg/0.015 mg per day. (URLD: Climara Pro® Transdermal System 0.045 mg/0.015 mg per day).
The ANDA has been designated by the USFDA as a Competitive Generic Therapy (CGT). The product is eligible for the 180-day exclusivity period available to certain first approved applicants under the CGT pathway, subject to the provisions of the U.S. Federal Food, Drug, and Cosmetic Act. Any exclusivity period, where applicable, would commence upon first commercial marketing of the product.
Estradiol and Levonorgestrel Transdermal System is primarily used treat moderate to severe symptoms of menopause. It is also used in postmenopausal women for prevention of osteoporosis. The product will be manufactured at the group's manufacturing plant at Moraiya, near Ahmedabad, Gujarat.
Zylidac Bio, a fully integrated biologics CDMO within the Zydus Lifesciences (Zydus) group, and Prolific Machines, a biotechnology company advancing biologics development and manufacturing through integrated optogenetics-enabled solutions delivering breakthrough yields, superior on-target quality, and precise process control, today announced a partnership to scale Prolific's platform from early development through GMP production. Both companies are headquartered in Emeryville in the San Francisco Bay Area.
Prolific's technology uses light to control protein expression in engineered cell lines, enabling substantial gains in productivity and product quality. The platform combines optogenetics enabled cell lines, illumination systems compatible with standard bioreactors, AI-driven process optimization, and advanced analytics. The technology is particularly useful for difficult-to express proteins including multi-specific antibodies, fusion proteins, cytokines and other complex modalities. Prolific has reported a record-breaking productivity milestone of 21 g/L in a 15-day intensified fed-batch CHO run for a monoclonal antibody (mAb) at small scale, along with up to three-fold titer increases for other complex formats.
Under the agreement, Zylidac Bio will first complete a tech transfer of Prolific's process at 50 liter scale to reproduce Prolific's results at the Zylidac site. The companies plan to subsequently scale client programs 250 liters, and into GMP manufacturing scale. Prolific's illumination hardware will work seamlessly with Zylidac's existing bioreactors, eliminating the need for customers to build new manufacturing infrastructure.
The partnership creates an end-to-end development and manufacturing pathway for Prolific's clients, spanning early development through commercial-scale supply. Programs can start with cell line development at Prolific and move seamlessly a short distance to Zylidac for scale-up, drug substance and drug product manufacturing, fill-finish, and packaging.
Zydus Sunshine Lifesciences, the proposed joint venture between Zydus Lifesciences (Zydus) and Sunshine Healthcare, part of Sunshine Holdings PLC, signed an agreement with the Board of Investment of Sri Lanka on 13 October 2026 to establish a pharmaceutical manufacturing facility in the BOI zone in Horana, Sri Lanka.
Both companies had announced the formation of a Joint Venture on 26 June 2026. The project envisages a phased investment of over USD 20 million. The facility will be developed on a site of nearly four acres, with commercial operations expected to commence in 2028, subject to project timelines and relevant regulatory approvals.
In its first phase, the facility will manufacture oral solid dosage forms for the Sri Lankan market. The investment supports the Zydus' international presence and commitment to expanding access to quality medicines. Local manufacturing is expected to strengthen medicine supply chain resilience and support the availability of essential medicines in Sri Lanka.